Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x

Article  PubMed  Google Scholar 

Dostálová S, Sonka K, Smahel Z et al (2003) Cephalometric assessment of cranial abnormalities in patients with acromegaly. J Craniofac Surg 31:80–87. https://doi.org/10.1016/s1010-5182(02)00182-8

Article  Google Scholar 

Colao A, Grasso LFS, Giustina A et al (2019) Acromegaly. Nat Rev Dis Primers 5:20. https://doi.org/10.1038/s41572-019-0071-6

Article  PubMed  Google Scholar 

Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59:221–228. https://doi.org/10.1507/endocrj.ej11-0177

Article  CAS  PubMed  Google Scholar 

Obari A, Sano T, Ohyama K et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82–91. https://doi.org/10.1007/s12022-008-9029-z

Article  PubMed  Google Scholar 

Pedraza-Arévalo S, Gahete MD, Alors-Pérez E et al (2018) Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 19:179–192. https://doi.org/10.1007/s11154-018-9465-0

Article  PubMed  Google Scholar 

Puig-Domingo M, Bernabéu I, Picó A et al (2021) Pasireotide in the personalized treatment of acromegaly. Front Endocrinol 12:648411. https://doi.org/10.3389/fendo.2021.648411

Article  Google Scholar 

Donoho DA, Bose N, Zada G, Carmichael JD (2017) Management of aggressive growth hormone secreting pituitary adenomas. Pituitary 20:169–178. https://doi.org/10.1007/s11102-016-0781-7

Article  CAS  PubMed  Google Scholar 

Freda PU, Wardlaw SL, Post KD (1998) Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89:353–358. https://doi.org/10.3171/jns.1998.89.3.0353

Article  CAS  PubMed  Google Scholar 

Bruns C, Lewis I, Briner U et al (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707–716. https://doi.org/10.1530/eje.0.1460707

Article  CAS  PubMed  Google Scholar 

van der Hoek J, Lamberts SWJ, Hofland LJ (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156(1):S45–S51. https://doi.org/10.1530/eje.1.02350

Article  CAS  PubMed  Google Scholar 

Günther T, Tulipano G, Dournaud P et al (2018) International union of basic and clinical pharmacology. CV. somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev 70:763–835. https://doi.org/10.1124/pr.117.015388

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. https://doi.org/10.1210/jc.2014-2700

Article  CAS  PubMed  Google Scholar 

Melmed S (1990) Acromegaly. N Engl J Med 322:966–977. https://doi.org/10.1056/NEJM199004053221405

Article  CAS  PubMed  Google Scholar 

Zada G, Lin N, Laws ER (2010) Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroadenomas. Neurosurg Focus 29:E4. https://doi.org/10.3171/2010.7.FOCUS10155

Article  PubMed  Google Scholar 

Laws ER, Vance ML, Thapar K (2000) Pituitary surgery for the management of acromegaly. Horm Res 53(3):71–75. https://doi.org/10.1159/000023538

Article  CAS  PubMed  Google Scholar 

Salaun C, Foubert L, Vialatou M et al (1999) [Prognostic factors in the surgical management of acromegaly]. Ann Med Interne (Paris) 150:195–198

CAS  PubMed  Google Scholar 

Bhayana S, Booth GL, Asa SL et al (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290–6295. https://doi.org/10.1210/jc.2005-0998

Article  CAS  PubMed  Google Scholar 

Bando H, Sano T, Ohshima T et al (1992) Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39:355–363. https://doi.org/10.1507/endocrj1954.39.355

Article  CAS  PubMed  Google Scholar 

Mete O, Cintosun A, Pressman I, Asa SL (2018) Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol Off J US Can Acad Pathol Inc 31:900–909. https://doi.org/10.1038/s41379-018-0016-8

Article  CAS  Google Scholar 

Fougner SL, Casar-Borota O, Heck A et al (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76:96–102. https://doi.org/10.1111/j.1365-2265.2011.04163.x

Article  CAS  PubMed  Google Scholar 

Heck A, Emblem KE, Casar-Borota O et al (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52:333–343. https://doi.org/10.1007/s12020-015-0766-8

Article  CAS  PubMed  Google Scholar 

Petersenn S, Houchard A, Sert C et al (2020) Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 23:171–181. https://doi.org/10.1007/s11102-019-01020-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dogansen SC, Yalin GY, Tanrikulu S et al (2018) Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21:347–354. https://doi.org/10.1007/s11102-018-0877-3

Article  PubMed  Google Scholar 

Ezzat S, Caspar-Bell GM, Chik CL et al (2019) Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract 25:379–393. https://doi.org/10.4158/EP-2018-0500

Article  PubMed  Google Scholar 

Liu C-X, Wang S-Z, Heng L-J et al (2022) Predicting subtype of growth hormone pituitary adenoma based on magnetic resonance imaging characteristics. J Comput Assist Tomogr 46:124–130. https://doi.org/10.1097/RCT.0000000000001249

Article  PubMed  PubMed Central  Google Scholar 

Park YW, Kang Y, Ahn SS et al (2020) Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23:691–700. https://doi.org/10.1007/s11102-020-01077-5

Article  CAS  PubMed  Google Scholar 

Cuevas-Ramos D, Fleseriu M (2016) Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 10:227–239. https://doi.org/10.2147/DDDT.S77999

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonneville F, Rivière L-D, Petersenn S et al (2018) MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis. Eur J Endocrinol EJE. https://doi.org/10.1530/EJE-18-0254. -18-0254.R2

Article  PubMed  Google Scholar 

Scânteie C-L, Leucuţa D-C, Ghervan C (2021) The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI. Med Pharm Rep 94:425–433. https://doi.org/10.15386/mpr-1299

Article